Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance work on Wednesday 22nd May 2019 from 11:00 AM to 1:00 PM (GMT).

During this time our website performance may be temporarily affected. We apologise for any inconvenience this might cause and thank you for your patience.

Issue 2, 2019
Previous Article Next Article

DePEGylation strategies to increase cancer nanomedicine efficacy

Author affiliations


To maximize drug targeting to solid tumors, cancer nanomedicines with prolonged circulation times are required. To this end, poly(ethylene glycol) (PEG) has been widely used as a steric shield of nanomedicine surfaces to minimize serum protein absorption (opsonisation) and subsequent recognition and clearance by cells of the mononuclear phagocyte system (MPS). However, PEG also inhibits interactions of nanomedicines with target cancer cells, limiting the effective drug dose that can be reached within the target tumor. To overcome this dilemma, nanomedicines with stimuli-responsive cleavable PEG functionality have been developed. These benefit from both long circulation lifetimes en route to the targeted tumor as well as efficient drug delivery to target cancer cells. In this review, various stimuli-responsive strategies to dePEGylate nanomedicines within the tumor microenvironment will be critically reviewed.

Graphical abstract: DePEGylation strategies to increase cancer nanomedicine efficacy

Back to tab navigation

Publication details

The article was received on 14 Nov 2018, accepted on 03 Dec 2018 and first published on 04 Dec 2018

Article type: Minireview
DOI: 10.1039/C8NH00417J
Nanoscale Horiz., 2019,4, 378-387

  •   Request permissions

    DePEGylation strategies to increase cancer nanomedicine efficacy

    L. Kong, F. Campbell and A. Kros, Nanoscale Horiz., 2019, 4, 378
    DOI: 10.1039/C8NH00417J

Search articles by author